With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.324769-03-1,(3S,5R)-1-Benzyl-3,5-dimethylpiperidin-4-one,as a common compound, the synthetic route is as follows.
(3R,5S)-1-Benzyl-3,5-dimethyl-piperidin-4-one (from preparation 14) was dissolved in ethanol (200 mL) and di-tert-butyl dicarbonate (5.08 g, 23 mmol) was added, followed by palladium hydroxide on carbon (20% on carbon, 200 mg) and the reaction mixture placed under 40 atmosphere pressure of hydrogen and stirred overnight at room temperature. The reaction mixture was then filtered through a pad of Celite and Arbocel and concentrated in vacuo to afford a yellow oil which crystallised on standing to afford the title compound (5.2 g, 90%) of sufficient purity to use directly in the next stage (preparation 10). 1H NMR (400 MHz, CDCl3) delta 1.03 (6H, d), 1.49 and 1.52 [9H, 2¡Ás (Rotamers)], 2.48-2.76 (4H, m), 4.24-4.53 (2H, m).
324769-03-1, The synthetic route of 324769-03-1 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Pfizer Inc; US2005/176772; (2005); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem